MVA85A (original) (raw)

MVA85A (modified vaccinia Ankara 85A) is a vaccine against tuberculosis developed by researchers led by Professor Helen McShane at Oxford University. This vaccine produces higher levels of long-lasting cellular immunity when used together with the older TB vaccine BCG. Phase I clinical trials were completed and then phase II clinical trials took place in South Africa. Efficacy trials ran in parallel from 2009 to 2019. Results released in February 2013, were described as "disappointing", showing only a statistically insignificant prevention rate in infants.